Combination OZURDEX & EyLea vs. OZURDEX Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema (COLLIDE)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Aflibercept (Primary) ; Dexamethasone (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms COLLIDE
- 11 Nov 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 Aug 2019 Planned End Date changed from 1 Dec 2019 to 1 May 2021.
- 19 Aug 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Feb 2021.